Vermont Medicaid and tirzepatide
Zepbound for weight loss: no. Criteria cover obstructive sleep apnea shown by a sleep study, with a BMI over 30 and prescribed CPAP, without type 2 diabetes. Mounjaro for weight loss: no; for type 2 diabetes Vermont Medicaid must cover it. Read from Department of Vermont Health Access documents Nov 6, 2026.
In 2025 Vermont Medicaid paid for 2,783 tirzepatide prescriptions (Mounjaro, Zepbound), 16% of its GLP-1 prescriptions and 46th of the 50 states and DC. It reimbursed $2.8 million before rebates, $998 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 1,724 | $1.7 million | $990 |
| Zepbound | 1,059 | $1.1 million | $1,011 |
Tirzepatide in the states around Vermont
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Vermont | 17 | $69/moWellmedr | 2,783 | Medicaid Zepbound: No |
| Massachusetts | 16 | $69/moWellmedr | 269,389 | Medicaid Zepbound: No |
| New Hampshire | 17 | $69/moWellmedr | 9,302 | Medicaid Zepbound: No |
| New York | 17 | $69/moWellmedr | 218,875 | Medicaid Zepbound: No |



